ArticleTransplantation2008
Suppressive efficacy and proliferative capacity of human regulatory T cells in allogeneic and xenogeneic responses.
Article in Transplantation, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Genetically engineered porcine liver: a new era in transplantation.International journal of surgery (London, England) · 2026Article
- Regulatory T Cell-Based Adoptive Cell Therapy in Autoimmunity.International journal of molecular sciences · 2025Review
- The α-Gal epitope - the cause of a global allergic disease.Frontiers in immunology · 2024Review
- Regulatory T cells in autoimmune kidney diseases and transplantation.Nature reviews. Nephrology · 2023Review
- Treg-based immunotherapy for antigen-specific immune suppression and stable tolerance induction: a perspective.Immunotherapy advances · 2023Review
- Xenotransplantation: A New Era.Frontiers in immunology · 2022Review
- Xenogeneic and Stem Cell-Based Therapy for Cardiovascular Diseases: Genetic Engineering of Porcine Cells and Their Applications in Heart Regeneration.International journal of molecular sciences · 2020Review
- Identification, selection, and expansion of non-gene modified alloantigen-reactive Tregs for clinical therapeutic use.Cellular immunology · 2020Review
- The human T-cell proliferative response to triple-knockout pig cells in mixed lymphocyte reaction.Xenotransplantation · 2020Article
- Article
- Skin xenotransplantation: Historical review and clinical potential.Burns : journal of the International Society for Burn Injuries · 2018Review
- Immune Responses of HLA Highly Sensitized and Nonsensitized Patients to Genetically Engineered Pig Cells.Transplantation · 2018Article
- Clinical Grade Regulatory CD4Frontiers in immunology · 2018Review
- Donor-Reactive Regulatory T Cell Frequency Increases During Acute Cellular Rejection of Lung Allografts.Transplantation · 2016Article
- Initial in vivo experience of pig artery patch transplantation in baboons using mutant MHC (CIITA-DN) pigs.Transplant immunology · 2015Article
- Immunological challenges and therapies in xenotransplantation.Cold Spring Harbor perspectives in medicine · 2014Review
- Self-recognition of the endothelium enables regulatory T-cell trafficking and defines the kinetics of immune regulation.Nature communications · 2014Article
- New concepts of immune modulation in xenotransplantation.Transplantation · 2013Review
- Regulatory T-cell therapy in transplantation: moving to the clinic.Cold Spring Harbor perspectives in medicine · 2013Review
- Human dominant-negative class II transactivator transgenic pigs - effect on the human anti-pig T-cell immune response and immune status.Immunology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAn understanding of the mechanisms that suppress the human anti-pig cellular response is key for xenotransplantation. We have compared the ability of human regulatory T cells (Tregs) to suppress xenogeneic and allogeneic responses in vitro.
methodsHuman peripheral blood mononuclear cells (PBMC), CD4+ T cells, or CD4+ CD25- T cells were stimulated with irradiated human or wild type (WT) or alpha1,3-galactosyltransferase gene-knockout (GT-KO) pig PBMC in the presence or absence of human CD4+ CD25 high Tregs. In separate experiments, 5- (and 6)-carboxyfluorescein diacetate succinimidyl ester-labeled human CD4+ T cells were stimulated with human or pig PBMC. The expansion and precursor frequencies of allo- and xenoreactive Tregs were assessed by labeling with FoxP3 mAb and flow cytometric analysis.
resultsThe responses of human PBMC, CD4+ T cells, and CD4+ CD25- T cells to pig PBMC were stronger than to human PBMC (P<0.05). Human anti-GT-KO responses were weaker than anti-WT responses (P<0.05). Human CD4+ CD25 high Tregs suppressed proliferation of CD4+ CD25- T cells to both human and pig PBMC stimulator cells with the same efficiency. Alloreactive CD4+ CD25+ FoxP3 high responder T cells proliferated more than their xenoreactive counterparts (P<0.05), although xenoreactive CD4+ CD25+ T cells proliferated more than alloreactive cells (P<0.05). There was no difference in precursor frequency between allo- and xeno-reactive CD4+ CD25+ FoxP3 high cells.
conclusionsHuman T-cell responses to pig cells are stronger than to allogeneic cells. The human response to GT-KO PBMC is weaker than to WT PBMC. Although human Tregs can suppress both responses, expansion of CD4+ CD25+ FoxP3 high cells against pig PBMC is weaker than against human PBMC. More human Tregs may be required to suppress the stronger xenogeneic response.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.